來源:[1] Keros Therapeutics:一個潛在的投機機會 (NASDAQ:KROS) | Seeking Alpha (https://seekingalpha.com/article/4825839-kero ...)[2] Keros Therapeutics:一個潛在的投機機會 (NASDAQ:KROS) (https://seekingalpha.com/article/4636000-kero ...)[3] 赫茲發行2030年到期3.75億美元可交換優先票據 - Investing.com (https://vertexaisearch.cloud.google.com/groun ...)